1. Home
  2. APLM vs CLRO Comparison

APLM vs CLRO Comparison

Compare APLM & CLRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • CLRO
  • Stock Information
  • Founded
  • APLM 2016
  • CLRO 1983
  • Country
  • APLM United States
  • CLRO United States
  • Employees
  • APLM N/A
  • CLRO N/A
  • Industry
  • APLM Blank Checks
  • CLRO Radio And Television Broadcasting And Communications Equipment
  • Sector
  • APLM Finance
  • CLRO Technology
  • Exchange
  • APLM Nasdaq
  • CLRO Nasdaq
  • Market Cap
  • APLM 15.6M
  • CLRO 13.9M
  • IPO Year
  • APLM N/A
  • CLRO N/A
  • Fundamental
  • Price
  • APLM $9.75
  • CLRO $0.61
  • Analyst Decision
  • APLM Strong Buy
  • CLRO
  • Analyst Count
  • APLM 2
  • CLRO 0
  • Target Price
  • APLM $425.00
  • CLRO N/A
  • AVG Volume (30 Days)
  • APLM 102.2K
  • CLRO 345.9K
  • Earning Date
  • APLM 02-15-2025
  • CLRO 11-15-2024
  • Dividend Yield
  • APLM N/A
  • CLRO 81.63%
  • EPS Growth
  • APLM N/A
  • CLRO N/A
  • EPS
  • APLM N/A
  • CLRO N/A
  • Revenue
  • APLM $2,101,000.00
  • CLRO $12,584,000.00
  • Revenue This Year
  • APLM N/A
  • CLRO N/A
  • Revenue Next Year
  • APLM N/A
  • CLRO N/A
  • P/E Ratio
  • APLM N/A
  • CLRO N/A
  • Revenue Growth
  • APLM 70.54
  • CLRO N/A
  • 52 Week Low
  • APLM $6.50
  • CLRO $0.46
  • 52 Week High
  • APLM $105.00
  • CLRO $2.48
  • Technical
  • Relative Strength Index (RSI)
  • APLM 50.39
  • CLRO 61.16
  • Support Level
  • APLM $7.23
  • CLRO $0.52
  • Resistance Level
  • APLM $8.88
  • CLRO $0.64
  • Average True Range (ATR)
  • APLM 1.37
  • CLRO 0.04
  • MACD
  • APLM 0.21
  • CLRO 0.01
  • Stochastic Oscillator
  • APLM 57.91
  • CLRO 82.81

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About CLRO ClearOne Inc. (DE)

ClearOne Inc is a communications solutions company, which is engaged in designing, developing, and selling conferencing, collaboration, streaming, and digital signage solutions for audio, video, and visual communication. It sells its commercial products to end-users predominantly through a network of independent distributors, who in turn sell its products to dealers, systems integrators, and other resellers. Its products include DSP mixers, amplifiers, Video walls, professional cameras, and professional microphones among others. Geographically the firm has its business presence across the United States and international markets.

Share on Social Networks: